Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Opsumit (Macitentan) for Treatment of Pulmonary Arterial Hypertension (PAH)

Drug Name (Brand / Generic)

Opsumit / macitentan

Developed By

Actelion Pharmaceuticals

Therapy Class

Dual endothelin receptor antagonist (ERA)

Current Indication

Pulmonary arterial hypertension (PAH)

Market Sector

Cardiovascular

Development Status

Approved in the US and Canada
Expand
Close
Close
Close

Go Top